COVID-19 疫苗诱导的免疫：mRNA（BNT162b2）与灭活（CoronaVac）疫苗的头对头比较。
COVID-19 vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2) versus inactivated (CoronaVac) vaccines.
机构信息
Vaccines for Africa Initiative (VACFA), Institute of Infectious Disease and Molecular Medicine & School of Public Health & Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Network for Education and Support in Immunisation (NESI), Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
出版信息
Respirology. 2022 Apr;27(4):260-261. doi: 10.1111/resp.14236. Epub 2022 Feb 28.
Abstract
article
摘要
文章
相似文献
1
COVID-19 vaccine-induced immunity: Head-to-head comparison of mRNA (BNT162b2) versus inactivated (CoronaVac) vaccines.
Respirology. 2022 Apr;27(4):260-261. doi: 10.1111/resp.14236. Epub 2022 Feb 28.
2
Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study.
Thyroid. 2022 May;32(5):505-514. doi: 10.1089/thy.2021.0684. Epub 2022 Apr 7.
3
Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients.
BMC Med. 2022 Oct 14;20(1):339. doi: 10.1186/s12916-022-02548-1.
4
The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases.
Kidney Int. 2022 Oct;102(4):922-925. doi: 10.1016/j.kint.2022.07.018. Epub 2022 Aug 11.
5
Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
mSphere. 2022 Apr 27;7(2):e0091521. doi: 10.1128/msphere.00915-21. Epub 2022 Mar 14.
6
Impact of a delayed second dose of mRNA vaccine (BNT162b2) and inactivated SARS-CoV-2 vaccine (CoronaVac) on risks of all-cause mortality, emergency department visit, and unscheduled hospitalization.
BMC Med. 2022 Mar 17;20(1):119. doi: 10.1186/s12916-022-02321-4.
7
Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases.
Int J Chron Obstruct Pulmon Dis. 2023 Jan 19;18:47-56. doi: 10.2147/COPD.S394101. eCollection 2023.
8
Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
Emerg Infect Dis. 2022 Jun;28(6):1237-1240. doi: 10.3201/eid2806.220061. Epub 2022 Apr 14.
9
Why two doses of the BNT162b2 mRNA COVID-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA COVID-19 and other vaccines.
Panminerva Med. 2022 Mar;64(1):131-132. doi: 10.23736/S0031-0808.21.04286-5. Epub 2021 Jan 22.
10
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
引用本文的文献
1
Serosurveillance among urban slum and non-slum populations immunized with COVID-19 vaccines in Bangladesh.
Epidemiol Infect. 2024 Jan 5;152:e14. doi: 10.1017/S0950268823001942.
2
Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers.
Indian J Microbiol. 2023 Sep;63(3):361-368. doi: 10.1007/s12088-023-01098-1. Epub 2023 Sep 4.
3
BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac.
Viruses. 2023 Jul 12;15(7):1534. doi: 10.3390/v15071534.
4
Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh.
Front Immunol. 2023 Mar 9;14:1128330. doi: 10.3389/fimmu.2023.1128330. eCollection 2023.
5
Comparison of the Immune Responses to COVID-19 Vaccines in Bangladeshi Population.
Vaccines (Basel). 2022 Sep 8;10(9):1498. doi: 10.3390/vaccines10091498.
本文引用的文献
1
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet. 2022 Feb 5;399(10324):521-529. doi: 10.1016/S0140-6736(22)00094-0. Epub 2022 Jan 21.
2
A Narrative Review of COVID-19 Vaccines.
Vaccines (Basel). 2021 Dec 31;10(1):62. doi: 10.3390/vaccines10010062.
3
Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021.
Euro Surveill. 2022 Jan;27(2). doi: 10.2807/1560-7917.ES.2022.27.2.2101197.
4
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong.
Respirology. 2022 Apr;27(4):301-310. doi: 10.1111/resp.14191. Epub 2021 Nov 24.
5
Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis.
Sci Rep. 2021 Nov 23;11(1):22777. doi: 10.1038/s41598-021-02321-z.
6
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial.
Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23.
7
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
Int J Infect Dis. 2022 Jan;114:252-260. doi: 10.1016/j.ijid.2021.11.009. Epub 2021 Nov 17.
8
Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
Euro Surveill. 2021 Oct;26(41). doi: 10.2807/1560-7917.ES.2021.26.41.2100920.
Zotero 插件